Bulging eyes. Double vision. In thyroid eye disease, inflammation around the eyes affects both appearance and everyday life.
On October 15, Enspryng was approved in the United States for adults with thyroid eye disease. The antibody blocks the IL-6 receptor and has previously been used for the neurological condition neuromyelitis optica spectrum disorder, or NMOSD. Maintenance treatment is a subcutaneous injection every four weeks, which can be given at home after training. Approval announcement ↗
The trials supporting the approval need to be read separately.
Among patients with active disease, SatraGO-2 found that 52.9% of those receiving Enspryng, compared with 23.4% receiving placebo, had an improvement in eye protrusion of at least 2 millimetres at week 24. The difference was statistically significant. In SatraGO-1, however, the corresponding figures were 49.0% and 31.2%, and the trial did not meet its prespecified primary endpoint. The two trials cannot both be described as successes. Original trial report ↗
These results also do not establish that Enspryng is as effective as, or more effective than, the existing drug Tepezza. There was no head-to-head comparison. Tepezza acts on a different target, the IGF-1 receptor, and is given as eight infusions at three-week intervals. Tepezza prescribing information ↗
Using Enspryng at home still requires attention to infection risk and blood tests. Even so, it looks likely to be a more convenient option for patients who find visits to an infusion centre burdensome. Enspryng prescribing information ↗
We want to follow how this difference plays out in the market. Will patients switch from an existing drug, or will people who have not previously pursued treatment now begin?
A drug's value depends not only on improvements in efficacy, but also on how easy it is for patients to use. How much will that convenience translate into uptake and sales? Taking price and insurance coverage into account, this should be a useful case to follow.
Keep following this topic
v1 ·Enspryng expands into thyroid eye disease: a different target and a different way to treat
The US approved Enspryng for adult thyroid eye disease. SatraGO-2 met its primary endpoint, whereas SatraGO-1 did not. Maintenance dosing is a subcutaneous injection every four weeks, with home administration possible after training.
- New US indication approvedRecorded
- Track patient uptakeUnverified
- Compare indication-specific salesUnverified
Hypothesis and what would change it
The option of home subcutaneous dosing may support uptake among patients deterred by infusion visits and could broaden the market.
What would change our view: Reconsider the market-expansion hypothesis if uptake consists only of switches and treatment starts among previously untreated patients do not rise. Revenue growth alone does not isolate the effect of administration route.
These are not head-to-head trials with Tepezza and do not establish equivalence or superiority. Market expansion and the contribution of administration route to sales are unmeasured; price, coverage and prescribing conditions also affect uptake.
Following saves this topic to your account. It does not send email or push notifications.
Evidence & reading
Public sources checked for this edition. Linked pages may subsequently change.
- Satralizumab in thyroid eye disease: SatraGO-1 and SatraGO-2 trial report ↗Ophthalmology · 2026-09-07
- Tepezza US prescribing information ↗US Food and Drug Administration ·
- Enspryng US prescribing information, revised October 2026 ↗Genentech ·
- US approval of Enspryng for thyroid eye disease ↗Genentech · 2026-10-15
READER DISCUSSION
What does this change for you?
A question, a different reading, or a source we should consider. A short comment is welcome.
Comments are public only after editorial review. Comments, likes and reports are for people aged 18 or older. Sign-in is required; you choose a public display name. Reviews are not continuous. Discussion rules
Loading discussion…
Also in this issue
Contents →R&D Allocation
Looking across diseases for drugs that treat fibrosis
Comparing patient-derived skin and lung models may reveal shared drug responses and differences. The 3D-MOFIB plan brings indication selection into the discovery stage.
Frontier Science
Why does the same inflammation affect some fetuses but not others?
Within the same mother, acute changes appeared in only a subset of male fetuses. A mouse placental study raises questions about local conditions that shape developmental effects.